Patents by Inventor Anne Marie Foley

Anne Marie Foley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227764
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-a]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 24, 2020
    Publication date: July 21, 2022
    Inventors: Anne Marie Foley, Fabien Claude Lecomte, James Thomas Reuberson, Matthew Duncan Selby, Richard David Taylor, Paul Jonathan Hickford, Gareth Neil Brace
  • Publication number: 20220073485
    Abstract: A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 10, 2022
    Inventors: Anne Marie Foley, Jag Paul Heer, Fabien Claude Lecomte, Nathaniel Julius Thomas Monck, Matthew Duncan Selby, Mengyang Xuan, Lihu Yang
  • Patent number: 11052076
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 6, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Publication number: 20200138797
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 12, 2018
    Publication date: May 7, 2020
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Patent number: 9550737
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 24, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Patent number: 9309243
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20150203486
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 23, 2015
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20150152065
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 11, 2013
    Publication date: June 4, 2015
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Patent number: 8710054
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: April 29, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crepy, Anne Marie Foley, Richard Jeremy Franklin
  • Patent number: 8338592
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: December 25, 2012
    Assignee: UCB Pharma, S.A.
    Inventors: Rikki Peter Alexander, Karen Viviane Lucile Crépy, Anne Marie Foley, Richard Jeremy Franklin
  • Patent number: 8242116
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 14, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crépy, Anne Marie Foley, Richard Jeremy Franklin, Alan Findlay Haughan, Helen Tracey Horsley, William Mark Jones, Bénédicte Irma Léonce Frédérique Lallemand, Stephen Robert Mack, Trevor Morgan, Patrick Marie Ghislain Pasau, David Jonathan Phillips, Verity Margaret Sabin, George Martin Buckley, Kerry Jenkins, Benjamin Garfield Perry
  • Publication number: 20110003785
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: June 24, 2008
    Publication date: January 6, 2011
    Applicant: UCB PHARMA, S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crepy, Anne Marie Foley, Richard Jeremy Franklin
  • Publication number: 20100137302
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: June 26, 2007
    Publication date: June 3, 2010
    Applicant: UCB PHARMA S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crepy, Anne Marie Foley, Richard Jeremy Franklin, Alan Findlay Haughan, Helen Tracey Horsley, William Mark Jones, Benedicte Irma Leonce Frederique Lallemand, Stephen Robert Mack, Trevor Morgan, Patrick Marie Ghislain Pasau, David Jonathan Phillips, Verity Margaret Sabin, George Martin Buckley, Kerry Jenkins, Benjamin Garfield Perry
  • Publication number: 20020115692
    Abstract: Tryptophan derivatives of formula (1) are described: 1
    Type: Application
    Filed: November 20, 2001
    Publication date: August 22, 2002
    Inventors: Sarah Catherine Archibald, David Festus Charles Moffat, Martin Clive Hutchings, Anne Marie Foley